Clinical Trial Update: TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating TILT-123, an oncolytic adenovirus encoding TNFα and IL-2, in combination with lymphocyte-depleting chemotherapy and tumor-in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• TILT-123 (tilt-123)
• Tumor-infiltrating lymphocytes (TILs) (tumor-infiltrating lymphocytes)

Snippet

Sponsor: TILT Biotherapeutics Ltd. | Conditions: Metastatic Melanoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING